Johns Hopkins researchers have received $35 million in funding from the U.S. Department of Defense for two nationwide clinical trials totaling 1,100 people to test the effectiveness of outpatient treatment of convalescent blood plasma, which is a transfusion of a blood product from COVID-19 survivors. The plasma contains antibodies that may help the patient’s immune system fight the virus. More information: [ Ссылка ]

свернуть